Carregant...
Extent and patterns of off-label use of rituximab for SLE
Despite conflicting evidence from clinical trials, rituximab continues to be used off-label in the treatment of systemic lupus erythematosus (SLE). A new study has now investigated the use of this drug for SLE in Europe, including indications for use and patient characteristics.
Guardat en:
| Publicat a: | Nat Rev Rheumatol |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5476200/ https://ncbi.nlm.nih.gov/pubmed/27872475 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrrheum.2016.191 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|